Sarilumab (Kevzara) in RA Patients with Recent Cancer History
Yes, sarilumab can be used safely in this clinical scenario and represents a reasonable alternative to rituximab, particularly given the practical barrier of infusion center unavailability. Both major rheumatology guidelines explicitly include sarilumab as an approved biologic DMARD option for RA treatment 1, 2, and emerging evidence suggests IL-6 inhibitors like sarilumab do not increase cancer recurrence risk in patients with prior malignancy 3.
Guideline Support for Sarilumab Use
The 2021 ACR guideline lists sarilumab among approved IL-6 receptor inhibitors for RA treatment alongside tocilizumab 1. The 2020 EULAR recommendations similarly endorse sarilumab as a standard bDMARD option when csDMARDs fail 2. Neither guideline restricts sarilumab use based on cancer history, and the 2025 EULAR update continues to support IL-6 inhibitors without specific cancer-related contraindications 4.
Cancer Safety Profile
The most critical consideration here is cancer recurrence risk. Recent comprehensive review data indicates that IL-6 inhibitors (including sarilumab) show no consistent association with increased cancer recurrence in RA patients with prior malignancy 3. This contrasts with JAK inhibitors, which demonstrated increased lung cancer risk in older patients with cardiovascular risk factors and should be avoided in your patient 3, 5.
The FDA label for Kevzara acknowledges that "the impact of treatment with KEVZARA on the development of malignancies is not known but malignancies were reported in clinical studies," noting this is a class effect of immunosuppression 6. However, this generic warning applies to all immunosuppressive DMARDs and does not represent a specific contraindication in patients with prior cancer.
Practical Advantages Over Rituximab
Sarilumab offers several advantages in your specific scenario:
- Subcutaneous administration every 2 weeks eliminates the infusion center requirement that makes rituximab impractical 6
- Comparable efficacy to other bDMARDs across multiple clinical endpoints 7, 8
- Can be used as monotherapy if csDMARD combination is problematic, though combination therapy is preferred 2
Dosing and Monitoring
Start with sarilumab 200 mg subcutaneously every 2 weeks in combination with a csDMARD (typically methotrexate) 1, 6. The 150 mg dose can be considered if laboratory abnormalities develop 9.
Critical monitoring parameters:
- Absolute neutrophil count (ANC) before initiation, then regularly—neutropenia is common (12-16% develop ANC <1.0 × 10⁹/L) but is not associated with increased infection risk in clinical trials 10, 8
- Liver transaminases (ALT/AST elevations occur frequently) 6
- Lipid panel (expect increases in total cholesterol, LDL, HDL) 6
- Infection surveillance (most common adverse events are upper respiratory infections, UTIs) 6
Key Safety Caveats
Do not use sarilumab if:
- Active infection is present 6
- ANC <2.0 × 10⁹/L, platelets <150 × 10⁹/L, or ALT/AST >1.5× upper limit of normal at baseline 6
- Active hepatic disease exists 6
Serious infections occurred in 0.6-1.1% of patients in controlled trials 8. The infection rate (105-110 events per 100 patient-years) exceeds placebo (81 per 100 patient-years) but is manageable with appropriate monitoring 6.
Comparison to Other Options
While rituximab might theoretically be preferred in some cancer contexts (particularly lymphoproliferative disorders where it has therapeutic benefit) 1, the practical barrier of infusion center access makes this moot. TNF inhibitors remain first-line options and show excellent safety in prior cancer patients 3, but if your patient has already failed or cannot tolerate TNFis, sarilumab represents a logical next step.
Abatacept showed slightly higher cancer risk than TNFis in recent US claims data (HR 1.47) 5, making sarilumab a potentially preferable choice among non-TNFi bDMARDs, though this finding requires confirmation and likely reflects channeling bias.
Treatment Algorithm
- Confirm no active infection or laboratory contraindications (check CBC, LFTs, lipids)
- Initiate sarilumab 200 mg SC every 2 weeks with background csDMARD
- Monitor ANC, LFTs at 4-8 weeks, then per clinical judgment
- Assess disease activity at 12 weeks—if inadequate improvement, consider switching to another bDMARD class
- Continue monitoring for infections throughout treatment, with lower threshold for evaluation given immunosuppression
The one-year cancer history warrants heightened surveillance for recurrence regardless of DMARD choice, but should not preclude sarilumab use based on current evidence.